NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
William G. Wierda(The University of Texas MD Anderson Cancer Center), Hema Sundar, Tanya Siddiqi(City Of Hope National Medical Center), Brian T. Hill(Cleveland Clinic), Claudio A. Mosse(Breast Cancer Research Foundation), Asher Chanan‐Khan(WinnMed), Randall S. Davis(University of Colorado Cancer Center), Jennifer A. Woyach(The Ohio State University), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Steven Coutré(Georgetown University), Jennifer R. Brown(Dana-Farber Cancer Institute), Deborah M. Stephens(University of North Carolina at Chapel Hill), Thomas J. Kipps(Moores Cancer Center), Danielle M. Brander(Duke University), Christopher D.�M. Fletcher(Harvard University), Farrukh T. Awan(The Ohio State University), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Paul Kaesberg(University of Wisconsin–Madison), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Herbert Eradat(Memorial Sloan Kettering Cancer Center), Nadia Khan(Fox Chase Cancer Center), Sameh Gaballa(Johns Hopkins Hospital), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Stephen J. Schuster(UPMC Hillman Cancer Center), Armin Ghobadi(Washington University in St. Louis), Muhammad Saad Hamid(Hayatabad Medical Complex), J Christine Ye(University of Michigan), Anthony Mato(Memorial Sloan Kettering Cancer Center), Greg Bociek(Susan Thompson Buffett Foundation), Mary A. Dwyer(National Comprehensive Cancer Network), Manali Kamdar(University of Colorado Cancer Center), S Bilgrami(Yale Cancer Center), Jeremy S. Abramson(Harvard University)
Cited by 84
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k